Interestingly, it has been proposed that the blockade of purinergic receptors might represent a therapeutic option to prevent the progression of severe COVID-19 (Di Virgilio et al., 2020; Kanthi et al., 2020; Illes, 2021). This evidence concerns the gene P2RX7 and COVID-19.